Trials / Completed
CompletedNCT01750580
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lirilumab | |
| DRUG | Ipilimumab |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2012-12-17
- Last updated
- 2015-07-22
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01750580. Inclusion in this directory is not an endorsement.